Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Veklury’s Normal Distribution in Japan to Start from Oct. 18
Japan will start the regular distribution of Gilead Sciences’ COVID-19 treatment Veklury (remdesivir) from October 18, some two months after the drug joined the NHI price list, according to a health ministry notification dated September 28. Since its special emergency…
To read the full story
Related Article
- Veklury Now Available in Normal Distribution Channel in Japan
October 19, 2021
- Evrysdi, Aimovig Now Available; Veklury’s Normal Distribution to Start around October
August 13, 2021
- Veklury Distribution via Govt Purchase to Continue for Now: MHLW
August 6, 2021
- August Listing OK’ed for Evrysdi, Veklury, Verquvo, 2 CGRP Migraine Meds and More
August 4, 2021
REGULATORY
- Japan Panel to Review Boehringer’s IPF Drug, Moderna COVID Shot on April 27
April 21, 2026
- Ferring Gene Therapy, Fujifilm Cell Product Inch Closer to Approval
April 21, 2026
- Japan Launches Panel to Promote Radiopharmaceuticals
April 21, 2026
- LDP Project Team to Seek Patent-Period Price Maintenance in Growth Strategy Proposal
April 21, 2026
- Zepbound’s OSA Indication Up for Panel Review on April 24
April 20, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…